Genomtec S.A. (FRA:4VI)

Market Cap	17.31M -30.4%
Revenue (ttm)	3.52K +1,400.0%
Net Income	-2.58M
EPS	-0.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,300
Average Volume	165
Open	1.040
Previous Close	1.008
Day's Range	1.014 - 1.400
52-Week Range	0.712 - 1.676
Beta	n/a
RSI	83.32
Earnings Date	Apr 30, 2026

About Genomtec

Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company’s flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 26
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4VI

Financial Performance

In 2024, Genomtec's revenue was 1,000, a change of 0.00% compared to the previous year's 1,000. Losses were -11.21 million, 24.4% more than in 2023.

Financial numbers in PLN